The UNICEF presentation provided an overview of the global HPV vaccine market, highlighting ongoing supply constraints since 2017 and expected stabilization by 2026. It detailed the five WHO-prequalified vaccines available for procurement, including products from GSK, Merck, Innovax, and the newly added Yuxi Zerun. The session reviewed long-term agreements (LTAs) for both Gavi-supported and middle-income countries, noting active negotiations to extend contracts beyond 2025. Pricing structures were outlined, emphasizing significant differences between Gavi-eligible and middle-income markets and the growing role of Chinese manufacturers in cost reduction. Finally, UNICEF underscored the importance of accurate five-year demand forecasts from countries to ensure timely procurement and secure affordable vaccine supply.